Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Flunitrazepam is described as extremely psychologically addictive with very high dependence potential. Compulsive redosing is commonly reported, and rebound anxiety following use can contribute to cycles of repeated use and dependence.
Physical dependence develops with regular use and can become severe. Sudden discontinuation is potentially life-threatening and may result in benzodiazepine withdrawal syndrome characterized by seizures, psychosis, insomnia, anxiety, tremors, sweating, nausea, and hallucinations. Gradual dose tapering over weeks is essential for safe discontinuation.
Flunitrazepam has relatively low acute toxicity when used alone, though Swedish studies suggest it may be more toxic than other benzodiazepines, finding it in approximately 16% of suicide cases involving benzodiazepines. Fatal overdose risk increases substantially when combined with other CNS depressants such as alcohol or opioids, which can cause fatal respiratory depression.
| Species | Route | Value |
|---|---|---|
| mouse | oral | 1200 mg/kg |
| rat | oral | 415 mg/kg |
Use during late pregnancy, especially at high doses, may result in fetal hypotonia (floppy baby syndrome) due to rapid placental transfer of the drug.
Paradoxical reactions including anxiety, agitation, confusion, disinhibition, and violent behavior occur rarely during use, with an incidence rate below 1% in the general population. These reactions are more frequent in recreational abusers, individuals with mental disorders, children, and those on high-dose regimes. Psychosis may also emerge as part of benzodiazepine withdrawal syndrome following abrupt discontinuation.
Flunitrazepam possesses anticonvulsant properties and generally suppresses seizures during use. However, paradoxical seizures may rarely occur, particularly in epileptics. Abrupt discontinuation after regular use poses a serious and potentially life-threatening seizure risk as part of benzodiazepine withdrawal syndrome; drugs that lower seizure threshold should be avoided during withdrawal.
Flunitrazepam was discovered at Hoffmann-La Roche as part of the benzodiazepine research program led by Leo Sternbach. The patent application was filed in 1960 and granted in 1962. Research during this period demonstrated that the specific molecular combination of an N-methyl group and 2-fluoro…
UN Convention on Psychotropic Substances 1971 (Schedule III)
Classified as a controlled drug requiring a valid prescription or license. Unauthorized possession may result in charges of trafficking in a drug of dependence. Only available in 1 mg tablets marketed under the brand name Hypnodorm.
Reclassified from Schedule III to Schedule I in 2012 under the Controlled Drugs and Substances Act. Production, distribution, and possession without authorization carry criminal penalties.
Available by prescription in both 1 mg and 2 mg tablet formulations. Generic alternatives exist for the higher dosage form.
Classified more strictly than most other benzodiazepines, which fall under Class 4. Available as a prescription medication in 0.5 mg and 1.0 mg tablet strengths.
Controlled under the Misuse of Drugs Act 1971 as a Class C substance and Schedule 4 under the Misuse of Drugs Regulations 2001. Approved for medical use and available by prescription.
Legal for medical use under the Arzneimittelgesetz (AMG). Possession or sale without a valid prescription is prohibited under the Suchtmittelgesetz (SMG).
Since November 2011, regulated under Anlage III of the Betäubungsmittelgesetz, requiring a special narcotic prescription form. Available in 1 mg tablets; 2 mg injectable ampoules are handled similarly to controlled narcotics like morphine.
Classified as a controlled substance available only by prescription. Marketed under the brand name Flunipam.
Listed as a controlled narcotic substance. Occasionally prescribed as a sleep aid for severe insomnia. Tablets are dyed green and blue to deter covert administration in beverages.
Federally classified as Schedule IV under the Controlled Substances Act, but the FDA has not approved it for medical use, effectively making possession without a valid foreign prescription illegal. Importation is banned even for individuals holding valid prescriptions from other countries. Several states including Idaho, Minnesota, and Oklahoma have independently classified it as Schedule I, carrying stricter penalties.
15 sources cited